razoxane has been researched along with Remission, Spontaneous in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (88.89) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
| Olweny, CL; Otim, D; Sikyewunda, W | 1 |
| Brunner, KW; Cavalli, F | 1 |
| Brugarolas, A; Buesa, JM; Gracia Marco, M; Lacave, AJ; Valle Pereda, M | 1 |
| Bates, T; Hellmann, K; Newton, KA; Ryall, RD | 1 |
| Bhavnani, M; Delamore, IW; Dhir, K | 1 |
| Shaw, D; Tudhope, GR | 1 |
| Hellmann, K; James, SE; Jones, S; Macdonald, E; Newton, KA; Ryall, RD | 1 |
| Ahmann, DL; Bisel, HF; Edmonson, JH; Frytak, S; Kvols, LK; Rubin, J | 1 |
1 trial(s) available for razoxane and Remission, Spontaneous
| Article | Year |
|---|---|
[New substances in oncologic therapy].
Topics: Altretamine; Ancitabine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Mitolactol; Nitrosourea Compounds; Razoxane; Remission, Spontaneous; Tamoxifen; Time Factors; Vinca Alkaloids; Zinostatin | 1978 |
8 other study(ies) available for razoxane and Remission, Spontaneous
| Article | Year |
|---|---|
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |
Further experience with rezoxane (ICRF 159; -- NSC --129943) in treating Kaposi's sarcoma.
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Leukopenia; Male; Middle Aged; Piperazines; Razoxane; Remission, Spontaneous; Sarcoma, Kaposi; Time Factors | 1980 |
Phase I and II clinical study of anhydro-ara-5-fluorocytosine (AAFC) and ICRF-159 combination in adenocarcinoma of digestive origin.
Topics: Adenocarcinoma; Adult; Aged; Ancitabine; Bone Marrow; Cytarabine; Digestive System Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Razoxane; Remission, Spontaneous | 1978 |
Combination of radiotherapy and razoxane (ICRF 159) for chondrosarcoma.
Topics: Adult; Aged; Bone Neoplasms; Chondrosarcoma; Female; Humans; Male; Middle Aged; Piperazines; Radiotherapy, High-Energy; Razoxane; Remission, Spontaneous; Soft Tissue Neoplasms; Time Factors | 1979 |
Razoxane in treatment of acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Humans; Leukemia, Myeloid, Acute; Middle Aged; Piperazines; Razoxane; Remission, Spontaneous | 1978 |
Razoxane in treatment of acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Piperazines; Razoxane; Remission, Spontaneous | 1978 |
Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.
Topics: Adult; Aged; Female; Humans; Leukopenia; Male; Middle Aged; Piperazines; Radiotherapy, High-Energy; Razoxane; Recurrence; Remission, Spontaneous; Sarcoma; Soft Tissue Neoplasms | 1978 |
Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
Topics: Cisplatin; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Kidney; Male; Melanoma; Middle Aged; Piperazines; Razoxane; Remission, Spontaneous; Triazenes | 1978 |